Home Interviews Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”

Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”

Cereno granted approval to initiate  Phase I trial with CS014

Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”

20 June, 2024

Cereno Scientific is a biotech company developing treatments for the number one killer in the world – cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 – a novel epigenetic HDAC inhibitor. Cereno’s CEO Sten R Sörensen stopped by the BioStock Studio to share more details about the news.

Watch the interview with Cereno‘s CEO Sten R Sörensen below:

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev